Barclays Has Lowered Expectations for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its target price decreased by equities research analysts at Barclays from $69.00 to $65.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price target suggests a potential upside of 16.93% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Bank of America upped their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group began coverage on shares of Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target for the company. Wells Fargo & Company lowered their price objective on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Finally, Guggenheim reissued a “buy” rating on shares of Bruker in a report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $74.09.

Bruker Stock Down 0.8 %

BRKR stock opened at $55.59 on Monday. The business has a 50 day moving average of $58.32 and a 200 day moving average of $61.04. The firm has a market cap of $8.43 billion, a PE ratio of 26.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.30% of the company’s stock.

Institutional Trading of Bruker

Institutional investors and hedge funds have recently modified their holdings of the company. Sanctuary Advisors LLC purchased a new stake in Bruker during the 2nd quarter valued at approximately $296,000. GAMMA Investing LLC grew its stake in Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 388 shares in the last quarter. CWM LLC increased its holdings in Bruker by 191.9% in the 3rd quarter. CWM LLC now owns 13,942 shares of the medical research company’s stock valued at $963,000 after acquiring an additional 9,165 shares during the last quarter. UMB Bank n.a. lifted its stake in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares in the last quarter. Finally, Rheos Capital Works Inc. bought a new position in shares of Bruker during the 3rd quarter valued at about $3,453,000. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.